Pfizer Levetiracetam Injection

Adult dose

Levetiracetam treatment may be initiated by intravenous or oral administration. The total daily dose and frequency of administration should remain the same. The injectable formulation is administered intravenously only and infused over 15 minutes using 100mL of diluent. For monotherapy, adults and adolescents aged 16 years or older should start with 250mg twice daily and increase to 500mg twice daily after 2 weeks. The dose may be increased by 500mg per day every 2 weeks, up to a maximum of 3000mg per day. For adjunctive therapy, adults and adolescents with partial-onset seizures should start with 500mg twice daily. The dose may be increased or decreased by 1000mg per day every 2 to 4 weeks, up to a maximum of 3000mg per day. For primary generalized tonic-clonic seizures, adults and adolescents should start with 500mg twice daily. The dose should be increased by 1000mg per day every 2 weeks, up to a maximum of 3000mg per day. For patients with renal impairment, adjust the dose according to creatinine clearance: normal (≧80), 500-1500mg twice daily; mild (50-79), 500-1000mg twice daily; moderate (30-49), 250-750mg twice daily; severe (<30), 250-500mg twice daily; end-stage renal disease patients on dialysis, 500-1000mg once daily. The film-coated tablets and oral solution are administered orally and should be taken with plenty of water, with or without food. Divide the daily dose into 2 equal doses.

Child dose

For adjunctive therapy in pediatric patients aged 16 years or older (myoclonic seizures), start with 500mg twice daily. Increase the dose by 1000mg per day every 2 weeks up to the recommended daily dose of 3000mg. Efficacy has not been studied at doses below 3000mg per day. The injectable formulation is not recommended for children under 16 years of age. Tablet administration is not applicable to children 4 years of age or younger, and the oral solution should be administered to infants aged 1 month or older. Oral formulations are not recommended for infants under 1 month of age. For pediatric patients with renal impairment and adolescents weighing less than 50kg, dose adjustment depends on creatinine clearance: normal (≧80), 10-30mg/kg twice daily; mild (50-79), 10-20mg/kg twice daily; moderate (30-49), 5-15mg/kg twice daily; severe (<30), 5-10mg/kg twice daily; end-stage renal disease patients on dialysis, 10-20mg/kg once daily.

This medication is used for the treatment of epilepsy, and there is a risk of suicidal thoughts or behaviors while taking it, so patients and caregivers should immediately inform a doctor if such symptoms arise. Additionally, this medication may cause neurological and psychiatric adverse reactions such as drowsiness, fatigue, coordination disorders, and behavioral changes, so caution is advised. Sudden discontinuation of this medication may result in increased seizure frequency; therefore, the dosage should be gradually reduced according to the physician's instructions. Patients allergic to this medication or similar drugs should not take it. Patients with depression or suicidal thoughts should consult with their doctor before taking this medication, and dosage adjustments may be necessary for patients with impaired kidney function. Regular blood tests to monitor white blood cell counts and other parameters are recommended. Drowsiness or decreased concentration may occur during treatment, so caution is needed when driving or operating hazardous machinery. It is advisable to avoid using this medication during pregnancy, and those breastfeeding should consult a doctor to decide whether to continue taking it since the medication may be passed through breast milk. For children, this medication should be administered in liquid form from the age of 1 month, and tablets are not recommended for children under 4 years old. Symptoms of overdose may include drowsiness or coma, and immediate medical attention should be sought. This medication does not have significant drug interactions with other antiepileptic medications or oral contraceptives; however, caution should be exercised regarding changes in blood concentration when used in combination with methotrexate. If any unusual behavior or mood changes occur during treatment, immediate consultation with healthcare professionals is essential, and regular check-ups are important for safe treatment.

• suicidal ideation
• suicidal behavior
• depression
• abnormal changes in mood and behavior
• drowsiness
• fatigue
• coordination impairment
• behavioral abnormalities
• asthenia
• psychotic symptoms

This medication should be stored in a sealed container to prevent contact with air and kept at a cool temperature below 25 degrees Celsius. This helps maintain the effectiveness of the medication and prevents degradation.

Appearance

A clear, colorless liquid in a clear, colorless vial for injection.

Package unit

5mL X 10 vials